Microba Life Sciences Ltd

Microba Investor Hub - Webinars

Microba Investor Hub

Microba Investor Hub - Corporate Governance

Microba Investor Hub - Shareholder Information

Corporate

Microba Investor Hub - News & Media

Microba Investor Hub - Announcements

DM Sans

Analyst Report - Capital Markets - 2Q24 - all eyes on Sonic, Invivo and MetaXplore execution.pdf

MAP reported its 2Q24 result, beating expectations at the top line driven by personalised testing sales. The company has successfully curated a leading groupvof international partners, including Sonic, Synlab, Genova, G42 and Gingko. This approach to driving distributor-led sales helps increase geographic reach without substantial input costs, noting Sonic and Gingko will likely be the most active partners given their financial alignment via respective shareholdings. We look forward to ongoing improvements in diagnostic sales, especially given progress over the last quarter and as Invivo synergies come into play. We expected Sonic to have an impact on sales growth in 2H24, with the now-demonstrated early success of the MetaXplore launch in Australia. The therapeutic segment is still early stage and represents a very high-risk, high-reward opportunity in the much longer term, in our view. Early safety data is encouraging and supportive of progression to further clinical testing.

Analyst Report - Capital Markets - 2Q24 - all eyes on Sonic, Invivo and MetaXplore execution